Table 2.
Liver biochemical of COVID-19 patients at different disease severity.
| References | Country | Group | Patients (n) | ALT (U/L) | AST (U/L) | GGT (U/L) | ALP (U/L) | LDH (U/L) | ALB (g/L) | TBIL (μmol/L) |
|---|---|---|---|---|---|---|---|---|---|---|
| Du et al.75 | Wuhan, China | Survivors | 158 | 22 (14–41) | 28 (19–42) | 29 (17–55) | NA | NA | 33 (31–38) | 9 (7–12) |
| Deceased | 21 | 27 (20–37) | 40 (27–62)* | 23 (17–42) | NA | NA | 33(31–36) | 10 (8–16) | ||
| Survivor | 137 | 27(15–40) | NA | NA | NA | 254 (219–318) | 34 (31–36) | NA | ||
| Zhou et al.12 | Wuhan, China | Non-survivor | 54 | 40(24–51)* | NA | NA | NA | 521 (363–669)* | 29 (27–31)* | NA |
| Lei et al.54 | China | Non-severe | 4585 | 23(15–38) | 22(17–31) | NA | 65(51–83) | NA | 38(35–41) | 10(8–14) |
| Severe | 1186 | 26(17–45)* | 31(21–46)* | NA | 63(50–84) | NA | 36(32–39)* | 11(8–15) | ||
| Wang et al.57 | Wuhan, China | Non-ICU | 102 | 23 (15–36) | 29 (21–38) | NA | NA | 212 (171–291) | NA | 9 (8–13) |
| ICU | 36 | 35 (19–57)* | 52 (30–70)* | NA | NA | 435 (302–596)* | NA | 12 (10–19)* | ||
| Wang et al.76 | Wuhan, China | Survivors | 274 | 28 (17–43) | 29 (22–43) | NA | NA | 286 (220–355) | NA | NA |
| Deaths | 65 | 24 (19–49) | 43 (30–68)* | NA | NA | 439 (360–643)* | NA | NA | ||
| Mo et al.77 | Wuhan, China | General | 70 | 20 (15–33) | 32 (23–38) | NA | NA | 241 (198–338) | 39 (36–42) | NA |
| Refractory | 85 | 28 (17–42) | 37 (25–56)* | NA | NA | 293 (193–434)* | 36 (32–40)* | NA | ||
| Cai et al.50 | Shenzhen, China | Non-severe | 240 | 30 (22–38) | 28 (19–37) | 34 (23–44) | 82 (49–98) | 168 (124.8–261.5) | NA | 14 (8–18) |
| Severe | 58 | 42 (28–78)* | 38 (23–66)* | 47 (31–152)* | 87 (54–106) | 227 (173–312)* | NA | 21 (13–25)* | ||
| Cai et al.2 | Shenzhen, China | Non-severe | 233 | 41 (23–65) | 34 (27–45) | 40 (25–61) | 69 (57–89) | NA | NA | 19 (13–26) |
| Severe | 85 | 67 (47–100)* | 58 (41–93)* | 92 (53–161)* | 79 (62–101) | NA | NA | 22 (18–28)* | ||
| Zheng et al.71 | Changsha, China | Non-severe | 131 | 19(15–18) | 23 (19–29) | NA | NA | 162(134–209) | NA | 11 (8–15) |
| Severe | 30 | 24 (18–35) | 32 (26–49)* | NA | NA | 226(194–315)* | NA | 13(9–17) | ||
| Zhang et al.58 | Wuhan, China | Mild | 84 | 21 (13) | 24 (10) | 29 (25) | 72(24) | 177(55) | 40(3) | 10 (4) |
| Severe | 31 | 38 (32)* | 39 (23)* | 57 (73)* | 80 (25) | 346 (257)* | 34 (4)* | 14 (6)* | ||
| Wu et al.78 | Jiangsu, China | Mild | 197 | 20 (16–38) | 26 (21–34) | NA | NA | 184 (155–262) | 42 (39–45) | 7 (5–12) |
| Severe | 83 | 24 (18–38) | 26 (23–39) | NA | NA | 235 (170–355)* | 38 (33–39)* | 7 (6–13) | ||
| Qian et al.72 | Shanghai, China | Non-severe | 298 | 22(15–32) | 23(18–31) | 24(15–41) | 57(48–67) | NA | 41(4) | 8(7–11) |
| Severe | 26 | 26(19–35) | 34(25–52)* | 28(21–63) | 59(48–70) | NA | 36(5)* | 11(9–15)* | ||
| Huang et al.61 | Jiangsu, China | Non-severe | 179 | 25(18–35) | NA | NA | NA | 226(174–357) | 41(38–45) | 10 (7–14) |
| Severe | 23 | 31(25–51)* | NA | NA | NA | 369(248–638)* | 38(34–41)* | 10(7–15) | ||
| Wan et al.79 | Chongqing, China | Mild | 95 | 22(15–37) | 22(17–31) | NA | NA | 212 (180–259) | 50 (37–44) | 9 (6–14) |
| Severe | 40 | 27 (154.5–33) | 34(26–44)* | NA | NA | 309 (254–408)* | 36(33–39)* | 10(8–16) | ||
| Chen et al.68 | China | Recovered | 161 | 20 (14.8–32) | 25 (20–33.3) | 28 (19–45.3) | 64 (51–77) | 268(214–317) | 36 (34–40) | 8 (6–11) |
| Deaths | 113 | 28 (18–47) | 45 (31–67) | 42 (27–70) | 76 (60–118) | 565(431–716) | 30 (28–33) | 13 (9–16) |
NA not available, ALT, alanine aminotransferase; AST, aspartate transaminase; GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; ALB, albumin; TBIL, total bilirubin abnormal.
*
P<0.05 compared to the other group.